Arbutus Biopharma Corporation is a biopharmaceutical company focused on the development of therapies to treat chronic hepatitis B virus (HBV) infection.
HBV is a significant global health issue, and Arbutus is dedicated to finding a functional cure for this chronic condition by targeting multiple aspects of the virus lifecycle. The company’s pipeline includes a combination of RNA interference (RNAi) therapies, capsid inhibitors, and oral small molecule antiviral agents, all designed to reduce the virus’s ability to replicate and promote immune system engagement.
Arbutus leverages its expertise in viral diseases and drug development to create innovative treatments that aim to achieve long-term control or cure of HBV. The company’s lead candidates, including AB-729 (an RNAi therapeutic) and AB-836 (a capsid inhibitor), are currently in various stages of clinical development.
Arbutus’s growth strategy is centered around advancing these candidates through clinical trials, exploring combination therapies, and potentially expanding its platform to address other viral diseases. With a strong focus on research and development and a commitment to addressing unmet medical needs, Arbutus Biopharma is well-positioned to make a significant impact in the fight against chronic HBV.
